GlassScriptPhysician profile
April Polite
NPI 1508565649
$2,313.26
in general payments reported to CMS, 2019-2025
25 companies · $1,062 in 2025
The $1,062 reported for 2025 was more than what 86% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $585 · 2024: $667 · 2025: $1,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,313.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $335.04 | 2023-2025 | |
| Eisai INC. | $285.49 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $250.43 | 2023-2025 | |
| Lundbeck LLC | $179.73 | 2024-2025 | Vyepti |
| Biogen, INC. | $176.15 | 2023-2025 | Vumerity, Tysabri, Skyclarys |
| Ucb, INC. | $168.77 | 2023-2025 | Rystiggo, Briviact |
| Amneal Pharmaceuticals LLC | $162.30 | 2023-2025 | Rytary, Ongentys 50mg Capsules 30, Crexont |
| Lilly USA, LLC | $120.75 | 2023-2025 | Amyvid, Kisunla, Reyvow |
| Vanda Pharmaceuticals INC. | $91.85 | 2025 | Ponvory |
| Impel Pharmaceuticals INC. | $56.79 | 2023 | Trudhesa |
| Celgene Corporation | $54.61 | 2023-2025 | Zeposia |
| Pfizer INC. | $54.15 | 2023-2024 | |
| Sk Life Science, INC. | $53.24 | 2023 | |
| Ge Healthcare | $49.62 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $43.34 | 2023 | Ultomiris |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $40.50 | 2024 | |
| Tanabe Pharma America, INC. | $37.09 | 2023-2024 | |
| Axsome Therapeutics, INC. | $28.92 | 2025 | Symbravo |
| Amgen INC. | $20.32 | 2025 | Uplizna |
| Ns Pharma, INC. | $19.86 | 2024 | Viltepso |
| Biotronik Nro, INC. | $18.72 | 2024 | Prospera |
| Takeda Pharmaceuticals U.S.A., INC. | $18.65 | 2024 | Hyqvia |
| Medtronic, INC. | $17.41 | 2024 | Intellis Adaptivestim |
| Neurocrine Biosciences, INC. | $15.17 | 2025 | |
| Janssen Biotech, INC. | $14.36 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Polite listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.